Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9672085 | 0.89 | HRH3 (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7395296 | 0.88 | GABRP (0.47) | CA2CA12CA3CA6CA9 | |
| SCHEMBL7030337 | 0.85 | TSHR (0.46) | CA2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10454979 | 0.82 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21623418 | 0.82 | CYP2A6 (0.43) | CA2CA12CA3CA6CA9 | |
| SCHEMBL21623467 | 0.82 | CYP2A6 (0.43) | CA2CA12CA3CA6CA9 | |
| SCHEMBL78831 | 0.82 | CA2 (0.48) | CA2CA12CA3CA6CA9 | |
| SCHEMBL24300824 | 0.80 | ASIC3 (0.48) | ENPP2GSK3B | |
| SCHEMBL21623461 | 0.80 | FFAR1 (0.42) | CA2CA12CA3CA6CA9 | |
| SCHEMBL8441768 | 0.80 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217708-B2 | Cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-05-15 | — | — | US | disclosed |
| EP-1389212-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1389213-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1550663-A1 | New crystalline forms of antiarrhythmic compounds | Astra Zeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| US-20050037067-A1 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | disclosed |
| US-20040132798-A1 | 3.7-Diazybicyclo [3.3.1] formulations as antiarrhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | US | disclosed |
| EP-1389211-A1 | 3,7-DIAZYBICYCLO 3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-1389213-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-1389212-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002083687-A1 | 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083689-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037067-A1 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds | CACNA1G, CACNA1I, CACNA1B | CA2 340/4885CA12 4142/4885CA3 318/4885 |
| US-20040132798-A1 | 3.7-Diazybicyclo [3.3.1] formulations as antiarrhythmic compounds | HCN3, CACNB3, TNNI3 | CA2 424/4885CA12 3795/4885CA3 266/4885 |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | SCN3A, KCNH1, CACNA1G | CA2 592/4885CA12 3840/4885CA3 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.